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Abstract
Introduction: Rheumatoid arthritis (RA) is frequently complicated with infections. The aim of our study was to evaluate 
vaccination response in patients with RA after B-cell depletion by using rituximab.
Methods: Influenza (Afluria) and pneumococcal polysaccharides (Pneumo23) vaccines were given 6 months after 
rituximab (post-RTX group, n = 11) or 6 days before rituximab treatment (pre-RTX group; n = 8). RA patients never 
exposed to RTX composed the control group (n = 10). Vaccine-specific cellular responses were evaluated on day 6 after 
vaccination, and vaccine-specific humoral responses, on day 21.
Results: On day 6 after vaccination, formation of influenza-specific B cells was lower in post-RTX group as compared 
with the pre-RTX group and controls (P = 0.04). Polysaccharide-specific B cells were found in 27% to 50%, being equally 
distributed between the groups. On day 21, the impairment of humoral responses was more pronounced with respect 
to influenza as compared with the pneumococcal vaccine and affected both IgG and light-chain production. Total 
absence of influenza-specific IgG production was observed in 55% of the post-RTX group.
Conclusions: RTX compromises cellular and humoral vaccine responses in RA patients. However, repeated RTX 
treatment or previous anti-tumor necrosis factor (anti-TNF) treatment did not accentuate these defects.
Introduction
Infections are one of the important causes of death in
rheumatoid arthritis (RA) [1-3]. For that reason, RA
patients are advised to be vaccinated against influenza
and pneumococci [4,5]. Antirheumatic treatment includ-
ing conventional disease-modifying drugs and TNF
inhibitors [6-8] may negatively affect the immunization
response. Inhibitor of folate metabolism, methotrexate
(MTX), impairs optimal immunization response, whereas
the effect of corticosteroids and azathioprine was less
pronounced [9,10]. The combination of MTX and TNF
inhibitors induces further deterioration of the immuniza-
tion response [8]. The use of rituximab (RTX), a mono-
clonal antibody targeting CD20-expressing B cells, is an
efficient novel strategy of RA treatment [11]. Preliminary
data suggest that RTX treatment may impair the response
to the influenza vaccine [11].
In this study, we evaluated the immunization response
in RA patients treated with RTX 6 days after immuniza-
tion and 6 months before immunization. We observed
that RTX treatment impairs B-cell functions regarding
cellular and humoral responses. RTX-treated patients
showed a disrupted production of vaccine-specific κ-light
chains in IgG subclass response with respect to protein
and polysaccharide antigens, as compared with controls.
However, the repeated courses of RTX treatment and dis-
tant exposure to TNF inhibitors induced no further
impairment of vaccine-specific response.
Materials and methods
Patients and vaccination
Twenty-nine RA patients visiting the Rheumatology
Clinic at Sahlgrenska University Hospital, Göteborg, were
prospectively enrolled in the study between January 2007
and June 2008 (Table 1). One of the patients in the control
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group was taking oral prednisolone medication, whereas
11 of 19 patients in the RTX-treated groups had predni-
solone (daily dose, 2.5 to 10 mg) (Tables 2 and 3). Ritux-
imab (Roche, Basel, Switzerland), 1,000 mg on days 1 and
15, was given intravenously in combination with 2 mg
tavegyl and 1 g orally given paracetamol.
All patients were vaccinated with Pneumo23, a prepa-
ration containing capsule polysaccharides of 23 pneumo-
coccal serotypes (MSD, Brussels, Belgium), and Afluria,
influenza vaccine (ZLB Pharma, Marburg, Germany),
administered intramuscularly. The patients were vacci-
nated 6 months after RTX treatment (post-RTX group, n
= 11), or 6 days before RTX treatment (pre-RTX group, n
= 8). As a control group, 10 patients never treated with
RTX were included. Blood samples were obtained from a
cubital vein on day 0, day 6, and day 21 after vaccination.
The ethics committee at the Sahlgrenska University of
Hospital approved this study. All patients gave written
informed consent for participation in the study.
Detection of vaccine-specific B cells was performed by
using the enzyme-linked immunosorbent spot
(ELISPOT), as described [12]. The 96-well nitrocellulose
filter plate (Millipore, Molsheim, France) coated with 10
μg/ml poly-L-lysine (Sigma, St. Louis, MO) was incu-
bated overnight with Pneumo23 (diluted 1 to 5) or Aflu-
ria (diluted 1 to 20). Cells were seeded in 1 × 105, 2 × 104,
4 × 103, and 8 × 102 cells/well and incubated for 12 hours.
Secreted immunoglobulins (Igs) were detected on a sin-
gle-cell level by using goat IgG anti-human IgG, IgA, and
IgM (Sigma). Each spot corresponded to one vaccine-
specific B cell enumerated with a microscope and pre-
sented as the median number of spot-forming cells (sfc)/
106 lymphocytes, with a confidence interval (CI) of 95%.
The sfc > 50 identified vaccination responders. We previ-
ously showed that in immunized RA patients, a cutoff > 5
sfc is safe; however, because we used B cell-depleted RA
patients, we increased the cutoff level to > 50 sfc [13].
Detection of vaccine-specific antibody production
T h e  9 6 - w e l l  p l a t e s  ( N u n c M a x i s o r b )  w e r e  c o a t e d  w i t h
Pneumo23 (diluted 1 to 5) and Afluria (diluted 1 to 20),
blocked and incubated overnight with samples diluted
1:300 and 1:1,200. Goat anti-human IgG1, IgG2 (both
Caltag Laboratories, Burlingame, CA), IgG3, IgG4 (both
Sigma), IgM-HRP (Jackson ImmunoResearch Laborato-
ries, West Grove, PA), total IgG, κ light chain (κ-chain)-
HRP, lambda light chain (λ-chain)-HRP (all from Dako
Immunoglobulins, Glostrup, Denmark) were used, fol-
lowed by an appropriate conjugate and substrate. The
plates were read at 405-nm and 450-nm wavelengths.
Samples drawn on days 0 and 21 were analyzed in paral-
lel; the comparison was done at the same sample dilution.
T he levels of vaccine-specific antibodies a t day 0 were
taken as 100%. On day 21, the mean increase of antibody
Table 1: Clinical and demographic parameters of patients with rheumatoid arthritis
Parameter Post-rituximab
(n = 11)
Pre-rituximab
(n = 8)
Controls
(n = 10)
Vaccination time 6 months after RTX 6 days before RTX No RTX
B cells (% of mononuclear cells 
in circulation) (mean ± SD)
2.2 ± 5.2 4.7 ± 4.1 6.1 ± 2.9
Age, years
(mean ± SD, range)
60.4 ± 7.8
(45-70)
65.4 ± 11.5
(55-82)
63.6 ± 12.9
(48-95)
Gender, m/f 1/10 1/7 3/7
Disease duration, years
(range)
17.3 ± 13.1
(6-33)
8.6 ± 5.5
(3-18)
7.4 ± 4.6
(2-16)
Erosive 10 (91%) 7 (87%) 9 (90%)
RF, positive 11 8 10
Treatment
MTX, n (mg/week, mean ± SD) 10 (17.7 ± 6.3)a 7 (18.7 ± 5.4)b 10 (18.3 ± 5.6)
Previous anti-TNF, n 10 5 2
Previous RTX, n 410
Time after previous RTX, 
months
30 months
(14-48)
24 months 0
MTX, Methotrexate; RF, rheumatoid factor; RTX, rituximab; SD, standard deviation; TNF, tumor necrosis factor.
aOne patient was receiving azathioprine treatment.
bOne patient was receiving chlorambucil treatment.Rehnberg et al. Arthritis Research & Therapy 2010, 12:R111
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levels in the control group was 110%. This value indicated
the cutoff level for vaccination response in the RTX-
treated patients.
Statistical analyses
Results are presented as median [CI 95%]. Continuous
parameters of the same patient over time were compared
by using the paired t test. The groups were compared by
using a Mann-Whitney test, and P values < 0.05 indicated
significant differences between the groups. All statistical
analysis was performed by using the Prism 5 software
(GraphPad Software, San Diego, CA, USA).
Results
Evaluation of B-cell numbers in the study groups
At the time of immunization, the numbers of circulating
B cells were evaluated by using flow cytometry. The num-
b e r s  o f  B  c e l l s  i n  p e r c e n t a g e s  i s  c a l c u l a t e d  b a s e d  o n
CD19+CD3- in the mononuclear population. The distri-
bution in the post-RTX, pre-RTX, and controls is shown
in Table 1.
Vaccine-specific cellular responses after RTX treatment
Cells secreting vaccine-specific Ig were enumerated 6
days after vaccination. At this time, the pre-RTX group
had not received RTX and was identical to controls.
Influenza = specific IgM B cells were prevalent in the pre-
RTX group (median sfc/106 lymphocytes, 55[0 to 1704]
and controls (sfc/106 lymphocytes 30[0 to 3,500]) as com-
pared with the post-RTX group (sfc/106 lymphocytes, 3[0
to 277]). Significantly decreased levels of influenza-spe-
cific IgM-secreting B cells were detected in the post-RTX
group versus controls (P = 0.046). In addition, when com-
paring the post-RTX group with the pre-RTX group, sig-
nificantly lower levels were found (P  = 0.044). No
differences were found between the pre-RTX group and
controls. The number of influenza-specific IgG- and IgA-
producing cells was similar, irrespective of RTX treat-
ment. Pneumo23-specific IgM-B cells were not found in
any group. The number of B cells producing Pneumo23-
specific switched Ig was lower (but not significant) as
compared with the influenza-specific B cells. No other
differences in Pneumo23-specific response were found
between the groups.
Vaccine-specific humoral responses after RTX treatment
The levels of vaccine-specific Ig were compared on days 0
and 21 (Table 3). We did not find any differences in the
increased influenza-specific IgM levels between the
groups. The levels of Pneumo23-specific IgM were ele-
vated in controls compared with day 0 (P < 0.05). No sig-
nificant increase of Pneumo23-specific IgM was found in
the RTX-treated groups.
On day 21, the mean levels of influenza-specific IgG
were significantly increased as compared with day 0 in
the post-RTX group (Table 3). When comparing influ-
enza-specific IgG levels in the pre-RTX group and con-
trols, no differences could be detected. A significant
increase of Pneumo23-specific IgG was observed in pre-
RTX group (P = 0.05) and controls (P = 0.037), whereas
P23-specific IgG production in the post-RTX group was
Table 2: Detailed information about medications used in the study 
cohort
Patients Prednisolone 
(mg/day)
MTX (mg/week) Other
Pre-RTX
1 0 12.5
25 2 5
37 . 5 2 0
46 . 2 51 0
51 0 2 0
Post-RTX
15 2 0
20 2 0 C y c l o s p o r i n  A
30 2 5
40 1 5
55 1 0
65 2 5
7 0 2.5 Azathioprine
80 1 0
9 2.5 22.5 Cyclosporin A
10 0 20
11 5 10
Controls
1 0 15 Sulfasalazine
25 1 0
3 0 25 Sulfasalazine
4 0 10 Hydroxychloro
kin + 
cyclosporin A
5 0 20 Hydroxychloro
kin
60 2 0 E t a n e r c e p t
70 2 0
8 0 25 Hydroxychloro
kin
9 0 20 Infliximab
10 0 20
MTX, methotrexate; RTX, rituximab.Rehnberg et al. Arthritis Research & Therapy 2010, 12:R111
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less pronounced. Pneumo23-specific IgG production was
significantly higher in the pre-RTX group as compared
with the post-RTX group (P = 0.027).
The post-RTX group was divided into patients treated
with RTX once (n = 7) or repeatedly RTX treated (twice
or more; n = 4), and the levels of vaccine-specific IgM and
IgG were compared. We observed no differences in the
levels of vaccine-specific Ig between the patients treated
with RTX once as compared with those who were treated
more than once, suggesting that repeated courses of RTX
induced no further impairment of the vaccine-specific
response.
Furthermore, dividing all RTX-treated patients into
those previously treated with TNF-inhibitors (n = 15) and
patients not treated with TNF-inhibitors (n = 4) revealed
no differences between these groups, suggesting that pre-
vious treatment with TNF inhibitors does not affect our
results.
IgG isotypes of vaccine-specific response to influenza and 
Pneumo23
The subclass analysis of IgG production showed that the
control group produced IgG1 and IgG4 influenza-specific
IgG (Figure 1). In contrast, when combining the RTX-
treated patients into one group, no subclass distinction in
IgG production could be detected. However, a substantial
part of these RTX-treated patients (five of 16; 31%) had
no increase of any influenza-specific IgG subclass on day
21 after vaccination (Table 4). Patients in the post-RTX
group had the lowest proportion of responders to influ-
enza of any IgG subclass (IgG1, four of 11; IgG2, six of 11;
IgG3, six of 11; and IgG4, four of 11) (Table 4). Interest-
ingly, four patients in the post-RTX group did not
respond in any IgG subclass against influenza immuniza-
tion. In contrast, only one patient in the pre-RTX group
and no one in the control group displayed a total lack of
IgG-subclass increase (Table 4).
For Pneumo23 vaccination, controls revealed a signifi-
cant increase of IgG2 and IgG3, whereas post-RTX
patients showed an isolated increase of IgG2, and pre-
RTX patients, of IgG4 (Figure 1). A total lack of IgG-sub-
class response against P23 was observed in four patients
in the post-RTX group, but none in the pre-RTX group or
in the control group (Table 4).
A previous course of RTX did not affect the immune
responses to influenza or P23, because only one of five
patients that did not respond to influenza had a previous
course of RTX, and two of four patients that did not
respond to P23 had a repeated course of RTX (Table 4).
No difference in IgG subclasses was observed in patients
with respect to previous treatment with TNF-α inhibi-
tors.
Vaccine-specific production of Ig light chains after RTX 
treatment
We measured the development of vaccine-specific light-
chains to evaluate functional B-cell populations in RTX-
treated patients. On day 21, the levels of influenza-spe-
cific Ig containing λ-chains (Ig-λ) were elevated in all
groups, irrespective of RTX treatment (Table 3). In con-
Table 3: Humoral response to vaccination on day 21 in RA patients treated with rituximab
Controls
n = 10
Pre-RTX
n = 8
Post-RTX
n = 11
Influenza vaccine, % increase
IgM, median (95% CI) responder, n 104 (96-130) 3 120 (98-139) 6 105 (88-132) 4
IgG, median (95% CI) responder, n 115 (96-191) 6 143 (72-176) 5 109 (85-139)a 5
κ-Light chain median (95% CI) 110 (101-145)a 126 (98-163) 105 (93-124)
λ-Light chain median (95% CI) 126 (98-175)a 147 (94-154)a 113 (93-199)a
Pneumococci vaccine
IgM, median (95% CI) responder, n 148 (92-541)a 8 107 (93-198) 3 105 (77-322) 5
IgG, median (95% CI) responder, n 126 (71-213)a 7 178 (102-335)a 6 107 (88-151)b 4
κ-Light chain median (95% CI) 154 (85/218)a 124 (97-211)a 105 (94-171)
λ-Light chain median (95% CI) 164 (98/571)a 227 (111-308)a 138 (88-330)a
Pre-RTX group, RA patients treated with RTX 6 days after vaccination; Post-RTX group, RA patients treated with RTX 6 months before vaccination; 
Controls, RA patients never treated with RTX. The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase 
of antibody levels in the control group was 110%. This value indicated the cutoff for vaccination response in the RTX-treated patients. CI, 
Confidence interval.
aIncrease of Ig levels on day 21 compared with day 0, P < 0.05.
bIncrease of Ig levels in post-RTX group was lower as compared with pre-RTX group, P < 0.027.Rehnberg et al. Arthritis Research & Therapy 2010, 12:R111
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Table 4: Individual responses of total IgG or IgG subclasses after influenza and pneumococcal polysaccharide 
immunization
Patients Total IgG IgG1 IgG2 IgG3 IgG4 Total IgG IgG1 IgG2 IgG3 IgG4 Previous RTX
Influenza P23
Pre-RTX
1 176 289 99 125 117 152 95 105 110 115 1
2 a 94 86 98 89 74 102 454 534 203 117 no
3 a 163 128 110 112 111 204 262 107 95 115 no
4 a 154 292 198 178 108 335 77 167 129 148 no
5 a 132 368 99 121 123 217 246 458 128 113 no
Post-RTX
1a 139 202 123 116 153 151 83 85 95 102 no
2 126 260 133 136 158 110 103 104 95 101 2
3 109 93 115 110 107 107 143 105 107 116 no
4 100 97 89 102 91 102 104 98 111 112 no
5a 115 89 72 100 96 93 87 211 112 108 no
6a 85 93 76 87 102 88 82 187 96 107 3
7 9 8 8 29 49 69 71 0 7 9 59 49 89 4n o
8 103 99 86 124 113 95 233 257 126 117 no
9a 104 102 115 91 103 126 92 105 92 98 1
10 127 222 115 160 170 104 159 248 175 206 2
11a 134 157 110 119 109 122 167 140 125 144 no
Controls
1 117 95 84 113 108 213 91 171 89 83 no
2a 191 252 96 125 127 115 897 521 235 278 no
3 100 157 100 50 105 139 137 178 109 95 no
49 6 145 97 105 113 136 467 216 159 137 no
5 121 205 101 191 126 105 114 112 107 111 no
6 116 124 123 108 119 97 154 136 151 112 no
7 113 123 179 111 111 71 316 259 120 122 no
8 174 234 127 146 121 161 167 140 108 105 no
99 7 9 8 7 2 144 123 111 65 84 114 101 no
10 99 142 116 129 124 194 271 122 132 889 no
aPrednisolone, 2.5-10 mg/day.
Controls, RA patients never treated with RTX; P23, pneumococcal polysaccharide vaccine 23; pre-RTX group, RA patients treated with RTX 6 days 
after vaccination; post-RTX group, RA patients treated with RTX 6 months before vaccination; RTX, rituximab.
The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase of antibody levels in the control group was 
110%. This value indicated the cutoff for vaccination response in the RTX-treated patients.
Bold numbers and gray boxes indicate levels equal to or greater than the cutoff level (110%).Rehnberg et al. Arthritis Research & Therapy 2010, 12:R111
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trast, influenza-specific Ig-κ was elevated only in controls
(P  = 0.001), but neither in post-RTX nor in pre-RTX
groups, suggesting that RTX may disrupt the production
of Ig-κ. The pattern of Pneumo23-specific Ig-κ was simi-
larly elevated in the pre-RTX group (P = 0.05) and in con-
trols (P = 0.01).
The pattern of light-chain production correlated to vac-
cine-specific IgG levels. None of six post-RTX patients
with the absence of an increase in influenza-specific IgG
subclasses developed increase in influenza-specific Ig-|
and Ig-| production. Only one of six patients had
repeated RTX treatments; thus, no accumulation of light-
chain suppression correlated with the number of RTX
treatments.
Discussion
In the present study we investigated the vaccine response
to protein (influenza) and polysaccharide (pneumococ-
cal) preparations in RA patients treated with RTX 6 days
after vaccination (pre-RTX group) and 6 months before
vaccination (post-RTX group). The response was com-
pared with that of RA patients never treated with RTX
(controls).
Previous reports on vaccination after RTX treatment
showed a detectable but reduced humoral response to
influenza in RA patients [11,14,15]. The vaccination time
point in those studies was chosen after RTX treatment
and corresponded to the post-RTX group in our study.
We chose the time point of 6 months after RTX treatment
because, at that time, antigen-naïve B cells
(CD19+IgD+CD27-) start repopulating the bone marrow
and circulation of RA patients [16]. The post-RTX group
had measurable amounts of B cells in peripheral blood.
Because we did not find any significant differences in fre-
quencies between any of the study groups, we draw the
conclusion that the immunization responses detected are
not due to different numbers of B cells in our study
groups. The vaccination time point corresponding to 6
days before RTX treatment (pre-RTX group) allowed us
t o  s t u d y  t h e  r o l e  o f  B  c e l l s  i n  t h e  e a r l y  e v e n t s  o f  t h e
immune response. During the first 6 days after vaccina-
tion, the primary antigen-specific B cells are formed.
These primary B cells express vaccine-specific Ig on the
surface, detected in our study with ELISPOT. However,
the primary B cells do not secrete vaccine-specific Ig,
because no antibody levels may be detected in the circu-
lation. It was previously shown in our laboratory that
antigen-specific B cells are detected in the circulation
between days 5 and 7 after vaccination and thereafter
migrate to peripheral lymphoid organs [13]. At this phase
of vaccine response, B cells were depleted in the pre-RTX
group, and humoral (mature) responses were evaluated in
these patients on day 21.
We observed that RTX treatment impairs B-cell func-
tions. RTX treatment reduced development of influenza-
specific B cells at the initial step of immune response, as
long as 6 months after RTX treatment. Notably, this
impaired cellular response resulted in a selective reduc-
Figure 1 Changes in IgG subclasses after protein and polysaccharide vaccination in rheumatoid arthritis (RA) patients before and after RTX 
treatment. (a) Changes at day 21 as compared with day 0 in immunoglobulin G (IgG)1-4 are shown after influenza vaccination. (b) Changes at day 21 
as compared with day 0 in IgG1-4 after P23 vaccination. In all figure parts, day 0 levels are set at 100%, and day 21 indicates changes relative to day 0. 
Dotted line indicates cutoff, set at 110%. Each dot corresponds to one patient, and statistical evaluation was performed by using the paired t test; sta-
tistical significance is set at P < 0.05. *P < 0.05; **P < 0.01; ***P < 0.0001.
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tion of IgM-expressing B cells, whereas the numbers of
influenza-specific IgG and IgA cells were not changed in
the post-RTX group. Because the numbers of B cells pro-
ducing IgG and IgA were unaffected, one could suggest
that a secondary vaccination response was observed,
characterized by the activation of already existing influ-
enza-specific memory B cells that had not been depleted
by the RTX treatment. Similar levels of influenza-specific
total IgG levels between the RTX-treated groups and
controls further support this hypothesis. However, half of
the post-RTX patients showed a total absence of vaccine-
specific IgG production in all subclasses. Interestingly,
the pre-RTX group developed an adequate humoral
response both to protein and to polysaccharide antigens.
Additionally, RTX-treated patients showed no distinction
in IgG-subclass response with respect to protein and
polysaccharide antigens present in controls. The influ-
enza-specific response in the controls was characterized
by production of IgG1  and IgG4. Such a distribution
between vaccine-specific IgG subclasses was not present
in RTX-treated patients, suggesting that RTX disrupted
the "normal subclass" pattern of IgG production.
In our previous study, we showed that RTX induces
total depletion of the antigen-naïve B-cell population
(CD19+IgD+CD27-), both in blood and in bone marrow of
RA patients [12]. To investigate further whether RTX
selects any B-cell subclass for elimination, we evaluated
light-chain production in RTX-treated patients after
immunizations. Interestingly, we observed that RTX-
treated patients had a disrupted production of vaccine-
specific κ-light chains. This finding may be due to either
an enhanced sensitivity to RTX of κ-light chain-express-
ing B cells, resulting in an enrichment of λ-light chain-
expressing B cells or a switch from κ-light chain to λ-light
chain production.
Another and more speculative and controversial theory
is that during RTX treatment, the B cell could switch
from κ-light chain to λ-light chain production in the
periphery after antigenic challenge. Further investiga-
tions are needed to confirm this theory. However, it has
been suggested that antigenic challenge, at least in the
bone marrow of mice, can cause a switch from κ-light
chain to λ-light chain, which indirectly may support our
findings [17,18].
Aiming to understand whether previous biologic treat-
ment contributed to the impaired B-cell function, we
compared vaccine-specific responses between the
patients treated with RTX once and those who were
treated repeatedly. We observed no differences in the lev-
els of vaccine-specific Ig between those groups, suggest-
ing that repeated courses of RTX induced no further
impairment of the vaccine-specific response. Addition-
ally, the RTX-treated groups included patients previously
exposed to and but for whom TNF inhibitors failed. The
vaccine-specific response in these patients was similar to
that in patients never exposed to TNF inhibitors, suggest-
ing that distant exposure to TNF inhibitors was unlikely
to contribute to the observed B-cell dysfunctions. This
suggestion is in concordance with previous reports of suf-
ficient humoral response to influenza vaccine in patients
treated with TNF-inhibitors [6,10,19].
Conclusions
In this study, we evaluated the vaccination response in
RA patients treated with RTX 6 days after vaccination
and 6 months before vaccination. We observed that RTX
treatment impairs B-cell functions regarding cellular and
humoral responses. RTX-treated patients showed a dis-
rupted production of vaccine-specific κ-light chains and
no distinction in IgG-subclass response with respect to
protein and polysaccharide antigens present in controls.
However, the repeated courses of RTX treatment and dis-
tant exposure to TNF inhibitors induced no further
impairment of the vaccine-specific response.
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